{
  "links": "https://www.ycombinator.com/companies/alixia",
  "name": "Alixia",
  "headline": "Targeting the Tumor Ecosystem to address cancer drug resistance.",
  "batch": "W22",
  "description": "Our compounds disrupt the metabolic and\r\ninflammatory triggers in both cancer and quasi-cancerous\r\ncells in the tumor microenvironment. By impacting multiple cell\r\ntypes, we are enabling effective, lasting cancer treatments.",
  "activity_status": "Active",
  "website": "http://www.alixia.com",
  "founded_date": 2022.0,
  "team_size": 2.0,
  "location": "San Francisco",
  "group_partner": null,
  "group_partner_yc": null,
  "company_linkedin": null,
  "company_twitter": null,
  "tags": "industry:biotech; industry:therapeutics; industry:drug-discovery; industry:oncology; industry:biotechnology; location:san-francisco-bay-area",
  "founders": [
    {
      "name": "Olof Mollstedt, Founder",
      "description": null,
      "linkedin": "https://www.linkedin.com/in/olof-mollstedt-95b4a1/"
    },
    {
      "name": "Helen Chen, Founder",
      "description": "Cancer & aging researcher | entrepreneur| mentor |",
      "linkedin": "https://www.linkedin.com/in/helen-y-chen-7951641/"
    }
  ],
  "status": true,
  "markdown": null,
  "generated_description": "**Alixia: Targeting Cancer at its Core**\n\nFounded in 2022 and part of the Y Combinator Batch W22, Alixia is a promising new player in the biotech field, located in the vibrant San Francisco Bay Area. With a compact team of just two, the company is tackling a giant hurdle in cancer treatment: drug resistance.\n\nAt its core, Alixia’s mission is ambitious yet focused—it's about disrupting the tumor ecosystem. Specifically, their approach targets the metabolic and inflammatory triggers in both cancerous and quasi-cancerous cells within the tumor microenvironment. By affecting multiple cell types, Alixia aims to enable treatments that are not just effective, but also durable.\n\nThe company is categorized under several relevant tags such as biotech, therapeutics, drug discovery, and oncology, reflecting its broad scope within the life sciences. With experienced backing from Y Combinator and the guidance of their Group Partner, Alixia is poised to innovate and drive progress in the field of cancer care.\n\nFor more insights and updates, you can visit their website at [alixia.com](http://www.alixia.com). As they continue to develop their solutions, Alixia exemplifies a new wave of biotech companies ready to challenge the status quo in cancer treatment."
}